You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 5, 2024

Investigational Drug Information for Peposertib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Peposertib?

Peposertib is an investigational drug.

There have been 15 clinical trials for Peposertib. The most recent clinical trial was a Phase 1 trial, which was initiated on July 27th 2020.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Leukemia. The leading clinical trial sponsors are National Cancer Institute (NCI), Merck KGaA, Darmstadt, Germany, and Merck KGaA.

There are four US patents protecting this investigational drug and one hundred and twenty-six international patents.

Recent Clinical Trials for Peposertib
TitleSponsorPhase
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid TumorsNational Cancer Institute (NCI)Phase 1
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaNational Cancer Institute (NCI)Phase 1
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine TumorsNational Cancer Institute (NCI)Phase 1

See all Peposertib clinical trials

Clinical Trial Summary for Peposertib

Top disease conditions for Peposertib
Top clinical trial sponsors for Peposertib

See all Peposertib clinical trials

US Patents for Peposertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Peposertib ⤷  Try a Trial Arylquinazolines Merck Patent GmbH (Darmstadt, DE) ⤷  Try a Trial
Peposertib ⤷  Try a Trial Arylquinazolines Merk Patent GMBH (Darmstadt, DE) ⤷  Try a Trial
Peposertib ⤷  Try a Trial PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Try a Trial
Peposertib ⤷  Try a Trial PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Peposertib

Drugname Country Document Number Estimated Expiration Related US Patent
Peposertib Argentina AR096235 2033-05-11 ⤷  Try a Trial
Peposertib Australia AU2014267723 2033-05-11 ⤷  Try a Trial
Peposertib Brazil BR112015027951 2033-05-11 ⤷  Try a Trial
Peposertib Canada CA2911668 2033-05-11 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.